These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 29741411)

  • 1. Biomarkers for severe allergic asthma in children: could they be useful to guide disease control and use of omalizumab?
    Amat F; Labbé A
    Expert Rev Respir Med; 2018 Jun; 12(6):475-482. PubMed ID: 29741411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study.
    Kallieri M; Papaioannou AI; Papathanasiou E; Ntontsi P; Papiris S; Loukides S
    Postgrad Med; 2017 Aug; 129(6):598-604. PubMed ID: 28427296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma.
    Kavati A; Zhdanava M; Ortiz B; Lecocq J; Schiffman B; Pilon D; Ho H; Lefebvre P; Stone B
    Clin Ther; 2019 Oct; 41(10):1956-1971. PubMed ID: 31563391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and effectiveness of omalizumab in the treatment of childhood asthma.
    Tortajada-Girbés M; Bousquet R; Bosque M; Carrera Martínez JJ; Ibáñez MD; Moreira A; Nieto A; Plaza AM; Rivas C; Requena G; Sánchez-Solis M; Tabar A; Torres-Borrego J; Zapatero L
    Expert Rev Respir Med; 2018 Sep; 12(9):745-754. PubMed ID: 30141696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study.
    Bhutani M; Yang WH; Hébert J; de Takacsy F; Stril JL
    PLoS One; 2017; 12(8):e0183869. PubMed ID: 28859150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of upper and lower airway eosinophilic inflammation with response to omalizumab in patients with severe asthma.
    Kurokawa M; Koya T; Takeuchi H; Hayashi M; Sakagami T; Ishioka K; Gon Y; Hasegawa T; Kikuchi T
    J Asthma; 2020 Jan; 57(1):71-78. PubMed ID: 30489179
    [No Abstract]   [Full Text] [Related]  

  • 7. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.
    Hanania NA; Wenzel S; Rosén K; Hsieh HJ; Mosesova S; Choy DF; Lal P; Arron JR; Harris JM; Busse W
    Am J Respir Crit Care Med; 2013 Apr; 187(8):804-11. PubMed ID: 23471469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting.
    Suzuki C; Lopes da Silva N; Kumar P; Pathak P; Ong SH
    J Med Econ; 2017 Aug; 20(8):832-839. PubMed ID: 28532191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study.
    Domingo C; Pomares X; Navarro A; Rudi N; Sogo A; Dávila I; Mirapeix RM
    Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.
    Zietkowski Z; Skiepko R; Tomasiak-Lozowska MM; Lenczewska D; Bodzenta-Lukaszyk A
    Int Arch Allergy Immunol; 2011; 154(1):25-32. PubMed ID: 20664274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma.
    Tajiri T; Matsumoto H; Gon Y; Ito R; Hashimoto S; Izuhara K; Suzukawa M; Ohta K; Ono J; Ohta S; Ito I; Oguma T; Inoue H; Iwata T; Kanemitsu Y; Nagasaki T; Niimi A; Mishima M
    Allergy; 2016 Oct; 71(10):1472-9. PubMed ID: 27113353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of omalizumab on patient reported outcomes, lung function, and inflammatory markers in severe allergic asthma.
    Frix AN; Schleich F; Paulus V; Guissard F; Henket M; Louis R
    Biochem Pharmacol; 2020 Sep; 179():113944. PubMed ID: 32240649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO.
    Chipps BE; Zeiger RS; Luskin AT; Busse WW; Trzaskoma BL; Antonova EN; Pazwash H; Limb SL; Solari PG; Griffin NM; Casale TB
    Ann Allergy Asthma Immunol; 2017 Dec; 119(6):524-532.e2. PubMed ID: 29054589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.
    Mansur AH; Srivastava S; Mitchell V; Sullivan J; Kasujee I
    Respir Med; 2017 Mar; 124():36-43. PubMed ID: 28284319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood Eosinophils, Fraction of Exhaled Nitric Oxide, and Serum Eosinophil Cationic Protein as Surrogate Markers for Sputum Eosinophils in Asthma: Influence of Treatment With Inhaled Corticosteroids.
    Alvarez Puebla MJ; Aroabarren Aleman E; Corcuera Garcia A; Ibañez Bereiz B; Iraola Iribar A; Olaguibel Rivera JM
    J Investig Allergol Clin Immunol; 2018 Jun; 28(3):210-212. PubMed ID: 29939147
    [No Abstract]   [Full Text] [Related]  

  • 16. The significance of eosinophil and eosinophil lymphocyte ratio (ELR) in predicting response to omalizumab treatment in patients with severe allergic asthma.
    Özgen H; Tepetam FM; Bulut İ; Örçen C
    Tuberk Toraks; 2021 Mar; 69(1):39-48. PubMed ID: 33853304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Airway inflammation and eotaxin in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.
    Zietkowski Z; Skiepko R; Tomasiak-Lozowska MM; Bodzenta-Lukaszyk A
    Adv Med Sci; 2011; 56(2):318-22. PubMed ID: 21940268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma.
    Arron JR; Choy DF; Scheerens H; Matthews JG
    Ann Am Thorac Soc; 2013 Dec; 10 Suppl():S206-13. PubMed ID: 24313774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneously elevated exhaled nitric oxide and serum-eosinophil cationic protein relate to recent asthma events in asthmatics in a cross-sectional population-based study.
    Mogensen I; Alving K; Bjerg A; Borres MP; Hedlin G; Sommar J; Dahlén SE; Janson C; Malinovschi A
    Clin Exp Allergy; 2016 Dec; 46(12):1540-1548. PubMed ID: 27513280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of omalizumab for the treatment of inadequately controlled severe allergic asthma in Chinese children.
    Zhou H; Lu Y; Wu B; Che D
    J Asthma; 2020 Jan; 57(1):87-94. PubMed ID: 30507328
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.